Healthy ageing in the time of COVID-19: A wake-up call for action.

Maturitas

Institute of Social and Preventive Medicine, University of Bern, Switzerland.

Published: June 2021

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847182PMC
http://dx.doi.org/10.1016/j.maturitas.2021.01.007DOI Listing

Publication Analysis

Top Keywords

healthy ageing
4
ageing time
4
time covid-19
4
covid-19 wake-up
4
wake-up call
4
call action
4
healthy
1
time
1
covid-19
1
wake-up
1

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Actinogen Medical, Sydney, Australia.

Background: Selecting the optimal dose for clinical development is especially problematic for drugs directed at CNS-specific targets. For drugs with a novel mechanism of action, these problems are often greater. We describe Xanamem's clinical pharmacology, including the approach to dose selection and proof-of-concept studies.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Merry Life Biomedical Company, Ltd., Tainan City, Taiwan, Taiwan.

Background: Alzheimer's disease (AD) is complex in pathogenesis and related to aging biology, especially in late-onset AD. We identified a novel synthetic curcumin analog TML-6 through the platform of 6 biomarkers of anti-aging, anti-inflammation, and anti-Aβ as the potential AD drug candidate. TML-6 exhibits multi-target effects on AD pathogenesis, including the activation of NrF-2, the regulation of autophagic machinery through mTOR, the inhibition of APP synthesis and reduction of Aβ, the upregulation of ApoE, and the inhibition of microglial activation.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

GSK, Stevenage, Hertfordshire, United Kingdom.

Background: Progranulin (PGRN), a glycoprotein secreted by microglia and neurons, regulates lysosomal function, neuroinflammation, and has neurotrophic effects. Variants in the granulin gene (GRN) that cause a reduction of PGRN in plasma and cerebrospinal fluid (CSF) are associated with an increased risk of Alzheimer's disease (AD). The sortilin receptor (SORT1) on neurons and microglia regulates PGRN degradation.

View Article and Find Full Text PDF

Background: People with dementia of all ages have a human right to equal access to quality health care. Despite evidence regarding its effectiveness, many people living with dementia lack access to evidence-based rehabilitation for promoting function and quality of life. The aims of this study were to 1) explore barriers to access to dementia rehabilitation; and 2) identify solutions which improve access to rehabilitation.

View Article and Find Full Text PDF

Background: Understand individuals' self-perception of aging is crucial for promoting a positive aging experience, better health with good quality of life, addressing activities participation, and can help by advocating policies and interventions that support the diverse needs of an aging population. This study aims to examine the validity and reliability of the Chinese version of BAPQ (C-BAPQ) for the healthy older people by assessing the content validity, test-retest reliability, and correlational analyses with mental health by Depression, Anxiety, and Stress Scale (DASS-21), quality of life by the Short Form 36 Health Survey (SF-36) and activity participation by the Model of Human Occupation Screening Tool (MOHOST). Moreover, to study the factor structure of the Chinese version of BAPQ (C-BAPQ) by using exploratory factor analysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!